<?xml version="1.0" encoding="UTF-8"?>
<p id="Par22">Consideration of overall long-term medical costs will need to take account of savings in treatment of hepatitis C due to successful therapy with the new antivirals. Many patients in developed countries with end-stage liver disease, in many cases due to hepatitis C, need a liver transplant. Unless action is taken to control hepatitis C, expensive as it may be in the short-term, total long-term health care costs are likely to rise. At the European level, the European Liver Patients Association (ELPA) has used a model simulating the public budget impact of increasing treatment coverage with newest DAAs in France and Romania [
 <xref ref-type="bibr" rid="CR9">9</xref>] to show that investing in the newest therapies is cost-effective, with short-term costs off-set in the longer run.
</p>
